TTK在肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2021.02.017

实用肿瘤学杂志 ›› 2021, Vol. 35 ›› Issue (2): 188-192.doi: 10.11904/j.issn.1002-3070.2021.02.017

• 综述 • 上一篇

TTK在肿瘤中的研究进展

秘嘉庆¹, 秦倩¹, 马惠涵¹, 马梅杰¹ 综述, 冯勤梅² 审校

1.山西医科大学(太原 030001);
2.山西医科大学附属人民医院妇产科

收稿日期:2020-07-22 修回日期:2020-10-10 出版日期:2021-04-28 发布日期:2021-04-27
通讯作者: 冯勤梅,E-mail:qinmei_feng@163.com
作者简介:秘嘉庆,女,(1996-),硕士研究生,从事妇科肿瘤的研究。

Research progress of threonine and tyrosine kinase in tumor

BI Jiaqing¹, QIN Qian¹, MA Huihan¹, MA Meijie¹, FENG Qinmei²

1. Shanxi Medical University,Taiyuan 030001,China;
2. Department of Obstetrics and Gynecology,The Affiliated People's Hospital of Shanxi Medical University

Received:2020-07-22 Revised:2020-10-10 Online:2021-04-28 Published:2021-04-27

摘要/Abstract

摘要： 苏氨酸和酪氨酸激酶(Threonine and tyrosine kinase,TTK)是纺锤体组装检查点的核心成分,许多研究发现TTK抑制剂可用于恶性肿瘤的治疗,在一些恶性肿瘤中可以与放化疗相结合提高治疗效果,并且TTK可以作为独立的生物标志物提示预后。本文对TTK抑制剂及其与放化疗联合应用于肿瘤治疗和TTK对肿瘤预后预测的研究进展进行综述。

关键词: TTK, 肿瘤治疗, 肿瘤预后

Abstract: Threonine and tyrosine kinase(TTK)are the core components of the spindle assembly checkpoint.Many studies have found that TTK inhibitors can be used in the treatment of malignant tumors.The combination of chemotherapy and radiotherapy improves the treatment effect,and TTK can be used as an independent biomarker to indicate prognosis.This article reviews the research progress of TTK inhibitors and their combined use with radiotherapy and chemotherapy in tumor therapy and TTK in predicting tumor prognosis.

Key words: TTK;Tumor treatment;Tumor prognosis

中图分类号:

R730.5

秘嘉庆, 秦倩, 马惠涵, 马梅杰, 冯勤梅. TTK在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 188-192.

BI Jiaqing, QIN Qian, MA Huihan, MA Meijie, FENG Qinmei. Research progress of threonine and tyrosine kinase in tumor[J]. Journal of Practical Oncology, 2021, 35(2): 188-192.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2021.02.017

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2021/V35/I2/188

参考文献

1 林玉华,倪振华.SPDEF与恶性肿瘤关系的研究进展[J].实用肿瘤学杂志,2020,34(2):185-188.
2 曹毛毛,陈万青.中国恶性肿瘤流行情况及防控现状[J].中国肿瘤临床,2019,46(3):145-149.
3 Rutledge SD,Cimini D.Consequences of aneuploidy in sickness and in health[J].Curr Opin Cell Biol,2016,40:41-46.
4 Fisk HA,Mattison CP,Winey M.A field guide to the Mps1 family of protein kinases[J].Cell Cycle,2014,3(4):437-440.
5 Lara-Gonzalez P,Westhorpe FG,Taylor SS.The spindle assembly checkpoint[J].Curr Biol,2012,22(22):966-980.
6 Lauzé E,Stoelcker B,Luca FC,et al.Yeast spindle pole body duplication gene Mps1 encodes an essential dual specificity protein kinase[J].EMBO J,1995,14(8):1655-1663.
7 Musacchio A.Spindle assembly checkpoint:the third decade[J].Phi Trans R Soc B,2011,366(1584):3595-3604.
8 Xie Y,Wang AQ,Lin JZ,et al.Mps1/TTK:a novel target and biomarker for cancer[J].J Drug Target,2017,25(2):112-118.
9 Stratford JK,Yan F,Hill RA,et al.Genetic and pharmacological inhibition of TTK impairs pancreatic cancer cell line growth by inducing lethal chromosomal instability[J].PLoS One,2017,12(4):e0174863.
10 Kaistha BP,Honstein T,Müller V,et al.Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells[J].Br J Cancer,2014,111(9):1780-1787.
11 Tang JN,Lu MX,Cui QX,et al.Overexpression of ASPM,CDC20,and TTK confer a poorer prognosis in breast cancer identified by gene co-expression network analysis[J].Front Oncol,2019,9:310.
12 Riggs JR,Nagy M,Elsner J,et al.The discovery of a dual TTK protein kinase/CDC2-like kinase(CLK2)inhibitor for the treatment of triple negative breast cancer initiated from a phenotypic screen[J].J Med Chem,2017,60(21):8989-9002.
13 King JL,Zhang BT,Li YX,et al.TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer[J].Oncogenesis,2018,7(9):69.
14 李倩,刘颖,郭君兰.红景天苷对人肺癌A549细胞裸鼠移植瘤生长的影响及对MAPK/ERK1/2信号通路的调控作用[J].中医学报,2020,35(7):1469-1476.
15 Chen XL,Yu CL,Gao J,et al.A novel USP9X substrate TTK contributes to tumorigenesis in non-small-cell lung cancer[J].Theranostics,2018,8(9):2348-2360.
16 Miao RY,Wu Y,Zhang HH,et al.Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer[J].Sci Rep,2016,6:33121.
17 梁若飞,杨彬彬,唐晓平.EN2在胶质母细胞瘤中的表达及其预后价值[J].现代肿瘤医学,2020,28(16):2783-2786.
18 Tannous BA,Kerami M,Vanderstoop PM,et al.Effects of the selective Mps1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugs[J].J Natl Cancer Inst,2013,105(17):1322-1331.
19 Maia ARR,de Man J,Boon U,et al.Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model[J].Ann Oncol,2015,26(10):2180-2192.
20 Argyriou AA,Koltzenburg M,Polychronopoulos P,et al.Peripheral nerve damage associated with administration of taxanes in patients with cancer[J].Crit Rev Oncol Hematol,2008,66(3):218-228.
21 Hilkens PH,Verweij J,Vecht CJ,et al.Clinical characteristics of severe peripheral neuropathy induced by docetaxel(Taxotere)[J].Ann Oncol,1997,8(2):187-190.
22 Wu ZX,Yang YQ,Wang GS,et al.Dual TTK/CLK2 inhibitor,CC-671,selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells[J].Cancer Sci,2020,111(8):2872-2882.
23 Maachani UB,Kramp T,Hanson R,et al.Targeting Mps1 enhances radiosensitization of human glioblastoma by modulating DNA repair proteins[J].Mol Cancer Res,2015,13(5):852-862.
24 Chandler BC,Speers C.A novel role for TTK in homologous recombination:implications for breast cancer radiosensitivity[J].Mol Cell Oncol,2020,7(3):e1737771.
25 Chandler BC,Moubadder L,Ritter CL,et al.TTK inhibition radiosensitizes basal-like breast cancer through impaired homologous recombination[J].J Clin Invest,2020,130(2):958-973.
26 Bie L,Zhao G,Cheng P,et al.The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression[J].PLoS One,2011,6(10):e25631.
27 Wang J,Xie YC,Bai XB,et al.Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastoma[J].Oncotarget,2018,9(3):3081-3088.
28 Xu QQ,Xu YL,Pan B,et al.TTK is a favorable prognostic biomarker for triple-negative breast cancer survival[J].Oncotarget,2016,7(49):81815-81829.
29 Zhang J,Li D,Zhang YM,et al.Integrative analysis of mRNA and miRNA expression profiles reveals seven potential diagnostic biomarkers for non-small cell lung cancer[J].Oncol Rep,2020,43(1):99-112.
30 Zheng L,Chen Zb,Kawakami M,et al.Tyrosine threonine kinase inhibition eliminates lung cancers by augmenting apoptosis and polyploidy[J].Mol Cancer Ther,2019,18(10):1775-1786.
31 Tsai YM,Wu KL,Chang YY,et al.Upregulation of Thr/Tyr kinase increases the cancer progression by neurotensin and dihydropyrimidinase-Like 3 in lung cancer[J].Int J Mol Sci,2020,21(5):1640.
32 Du LQ,Zhao ZZ,Suraokar M,et al.LMO1 functions as an oncogene by regulating TTK expression and correlates with neuroendocrine differentiation of lung cancer[J].Oncotarget,2018,9(51):29601-29618.
33 Kang T,Yan JH,Bao H,et al.Expression and clinical significance of TTK in cervical cancer[J].Int J Clin Exp Med,2018,11(11):12133-12140.
34 Guo Y,Zhang XJ,Xu QB,et al.Human papillomavirus 16 oncoprotein E7 retards mitotic progression by blocking Mps1-MAP4 signaling cascade[J].Oncogene,2019,38(31):5959-5970.
35 Chen F,Wu PK,Hu HL,et al.Protein kinase TTK promotes proliferation and migration and mediates epithelial-mesenchymal transition in human bladder cancer cells[J].Int J Clin Exp Pathol,2018,11(10):4854-4861.
36 Liu XD,Yao DW,Xin F.TTK contributes to tumor growth and metastasis of clear cell renal cell carcinoma by inducing cell proliferation and invasion[J].Neoplasma,2019,66(6):946-953.
37 Kusakabe K,Ide N,Daigo Y,et al.Discovery of imidazo[1,2-b]pyridazine derivatives:selective and orally available Mps1(TTK)kinase inhibitors exhibiting remarkable antiproliferative activity[J].J Med Chem,2015,58(4):1760-1775.
38 Tardif KD,Rogers A,Cassiano J,et al.Characterization of the cellular and antitumor effects of MPI-0479605,a small-molecule inhibitor of the mitotic kinase Mps1[J].Mol Cancer Ther,2011,10(12):2267-2275.
39 Feng H,Gu ZY,Li Q,et al.Identification of significant genes with poor prognosis in ovarian cancer via bioinformatical analysis[J].J Ovarian Res,2019,12(1):35.
40 Singh R,Som A.Identification of common candidate genes and pathways for progression of ovarian,cervical and endometrial cancers[J].Meta Gene,2020,23:100634.
41 Alberto O,Javier PP,Ana AS,et al.In silico analyses identify gene-sets,associated with clinical outcome in ovarian cancer:role of mitotic kinases[J].Oncotarget,2016,7(16):22865-22872.

[1]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[2]	李富荣,程先硕,李云峰. 靶向血管生成拟态治疗肿瘤的研究进展[J]. 实用肿瘤学杂志, 2015, 29(4): 359-363.
[3]	宗卫娇芦凤亮刘晔综述金艾顺审校. 全人源抗TRAIL-R1/-R2单克隆抗体肿瘤治疗的研究进展[J]. 实用肿瘤学杂志, 2014, 28(4): 344-348.
[4]	张,悦,张清媛,赵,红,汤大北,甄丽娜. 肿瘤特异性Th1细胞联合脂质体多肽抗肿瘤活性研究[J]. 实用肿瘤学杂志, 2013, 27(5): 391-395.
[5]	张翼翔, 马长宏综述, 王雯雯审校. 凋亡抑制蛋白Livin的最新研究与应用[J]. 实用肿瘤学杂志, 2009, 23(3): 275-277.
[6]	张依综述, 姜达审校. 间充质干细胞及其在肿瘤治疗中的应用[J]. 实用肿瘤学杂志, 2009, 23(3): 282-286.

TTK在肿瘤中的研究进展

Research progress of threonine and tyrosine kinase in tumor

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价